Axsome Therapeutics (AXSM)
72.32
+1.22 (1.72%)
Upcoming Events
Latest Headlines
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 17, 2024 9:00 PM - StreetInsider
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 7:00 AM - StreetInsider
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 12, 2024 2:30 AM - StreetInsider
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024 7:00 AM - StreetInsider
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 3, 2024 9:00 PM - StreetInsider
Form 4 Axsome Therapeutics, For: Apr 01 Filed by: Jacobson Mark L.
April 1, 2024 6:47 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.
April 1, 2024 6:14 PM - SEC Filing
Form 8-K Axsome Therapeutics, For: Mar 28
April 1, 2024 8:27 AM - SEC Filing
Axsome Therapeutics (AXSM) Initiates ENGAGE Phase 3 Trial of Solriamfetol
April 1, 2024 7:02 AM - StreetInsider
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 1, 2024 7:00 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $109 at Mizuho
March 28, 2024 6:29 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $127 at Citi
March 26, 2024 7:23 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $190 at H.C. Wainwright
March 26, 2024 6:36 AM - StreetInsider
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 25, 2024 9:00 PM - StreetInsider
Form 8-K Axsome Therapeutics, For: Mar 25
March 25, 2024 9:07 AM - SEC Filing
Form 8-K Axsome Therapeutics, For: Mar 25
March 25, 2024 9:03 AM - SEC Filing
Axsome Therapeutics (AXSM) Reports Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024 7:03 AM - StreetInsider
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024 7:00 AM - StreetInsider
Axsome Therapeutics (AXSM) Reports AXS-12 Met Primary Endpoint in the SYMPHONY Phase 3 Trial
March 25, 2024 6:31 AM - StreetInsider
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024 6:30 AM - StreetInsider
Form 8-K Axsome Therapeutics, For: Mar 19
March 19, 2024 7:06 AM - SEC Filing
Axsome Therapeutics (AXSM) Initiates PARADIGM Phase 3 Trial of Solriamfetol
March 19, 2024 7:03 AM - StreetInsider
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024 7:00 AM - StreetInsider
Baird Starts Axsome Therapeutics (AXSM) at Outperform, 'we anticipate the sales trajectory will remain strong'
March 18, 2024 4:26 PM - StreetInsider
Top pharma stocks to own in 2024 – Citi
March 17, 2024 8:00 PM - StreetInsider
Form 4 Axsome Therapeutics, For: Mar 14 Filed by: JEFFS ROGER
March 15, 2024 8:06 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: JEFFS ROGER
March 15, 2024 7:10 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: JEFFS ROGER
March 14, 2024 4:20 PM - SEC Filing
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 5, 2024 7:00 AM - StreetInsider
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: JEFFS ROGER
February 29, 2024 6:35 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: Saad Mark E
February 29, 2024 6:34 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: Jacobson Mark L.
February 29, 2024 6:34 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: Pizzie Nick
February 29, 2024 6:25 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: TABUTEAU HERRIOT
February 29, 2024 6:20 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: Mahony Susan
February 29, 2024 6:19 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Feb 27 Filed by: Murdock Hunter R.
February 29, 2024 5:40 PM - SEC Filing
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024 7:00 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Lowered to $108 at Mizuho Securities
February 27, 2024 6:37 AM - StreetInsider
Form 10-K Axsome Therapeutics, For: Dec 31
February 23, 2024 8:11 AM - SEC Filing
Axsome Therapeutics (AXSM) PT Lowered to $107 at UBS
February 21, 2024 8:42 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Lowered to $123 at RBC Capital
February 21, 2024 6:51 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $108 at Cantor Fitzgerald
February 20, 2024 4:32 PM - StreetInsider
Form 8-K Axsome Therapeutics, For: Feb 20
February 20, 2024 4:32 PM - SEC Filing
Axsome Therapeutics (AXSM) Misses Q4 EPS by 92c
February 20, 2024 7:11 AM - StreetInsider
Form 8-K Axsome Therapeutics, For: Feb 20
February 20, 2024 7:06 AM - SEC Filing
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024 7:00 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $112 at Mizuho Securities
February 15, 2024 6:26 AM - StreetInsider
Form SC 13G/A Axsome Therapeutics, Filed by: Fairmount Funds Management LLC
February 14, 2024 3:47 PM - SEC Filing
Form SC 13G/A Axsome Therapeutics, Filed by: RTW INVESTMENTS, LP
February 14, 2024 7:27 AM - SEC Filing
Form SC 13G/A Axsome Therapeutics, Filed by: VANGUARD GROUP INC
February 13, 2024 5:01 PM - SEC Filing
UBS Starts Axsome Therapeutics (AXSM) at Buy, 'Auvelity growth intact, ADA data attractive catalyst'
February 6, 2024 12:55 AM - StreetInsider
Form SC 13G/A Axsome Therapeutics, Filed by: BlackRock Inc.
January 26, 2024 5:26 PM - SEC Filing
RBC Capital Starts Axsome Therapeutics (AXSM) at Outperform
January 25, 2024 5:14 AM - StreetInsider
Full Article List
